Leaching from packaging prompts recall

Candace Stuart | | Cardiovascular Business | Structural Heart Disease

Novartis is recalling physician samples of medications used to treat hypertension and cholesterol because of contamination from a chemical used in packaging.

The FDA issued a Class II recall on physician sample bottles of the blood pressure pharmaceuticals Diovan (valsartan), Exforge (amlodipine and valsartan) and Tekturna (aliskiren) because tests showed the presence of a photocuring agent in the tablets.

The agent, Darocur 1173, is used in inks on shrink-wrap sleeves.

Candace Stuart, Contributor

Related Content

‘A victory for TAVR’: How treatment impacts elderly patients in their last year of life
CMS proposes Medicare coverage for transcatheter tricuspid valve replacement
Hydra TAVR valve gains key approval as global reach continues to grow
SAVR outperforms TAVR in patients with bicuspid aortic valves
Treating AFib patients with TAVR still linked to elevated risks
Heart surgeons detail world’s first robotic heart procedure of its kind

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.